<p>Amedisys, Inc.（納斯達克代碼：AMED - 獲取免費報告）在週四的交易量有所上升。中午交易時段交易了 1,188,750 股，較前一交易日的 377,256 股增加了 215%。該股票最後交易價格為 100.88 美元，之前收盤價為 99.29 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>一些股票分析師最近對 AMED 股票發佈了報告。加拿大皇家銀行在 4 月 16 日的研究報告中重申了對 Amedisys 的 “跑贏大盤” 評級，並設定了 100.00 美元的目標價。Wall Street Zen 在 5 月 24 日的研究報告中將 Amedisys 的評級從 “強力買入” 下調至 “買入”。</p>
<p><strong>查看我們最新的 Amedisys 股票報告</strong></p>
<h2>Amedisys 股票上漲 1.6%</h2>
<p>該公司的流動比率為 1.36，速動比率為 1.36，債務與股本比率為 0.26。該公司的 50 日簡單移動平均線為 97.08 美元，200 日簡單移動平均線為 94.31 美元。公司的市值為 33.2 億美元，市盈率為 39.25，市盈增長比率為 1.34，貝塔值為 0.89。</p>
<p>Amedisys（納斯達克代碼：AMED - 獲取免費報告）最後一次公佈財報是在 7 月 29 日，健康服務提供商報告每股收益（EPS）為 1.54 美元，超出市場普遍預期的 1.39 美元，超出 0.15 美元。Amedisys 的淨利潤率為 3.56%，股本回報率為 12.91%。該公司本季度的收入為 6.2186 億美元，而分析師預期為 6.1461 億美元。去年同期，該公司的每股收益為 0.98 美元。本季度的收入較去年同期增長了 5.2%。整體來看，股票研究分析師預計 Amedisys, Inc.在本財年的每股收益將達到 4.4 美元。</p>
<h2>對 Amedisys 的對沖基金觀點</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Hexagon Capital Partners LLC 在第一季度將其在 Amedisys 的持股增加了 108.1%。Hexagon Capital Partners LLC 現在擁有 310 股該健康服務提供商的股票，價值 29,000 美元，此前在上一季度增持了 161 股。MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在 Amedisys 的持股增加了 56.1%。MassMutual Private Wealth &amp; Trust FSB 現在擁有 334 股該健康服務提供商的股票，價值 31,000 美元，此前在上一季度增持了 120 股。Fifth Third Bancorp 在第一季度將其在 Amedisys 的持股增加了 68.1%。Fifth Third Bancorp 現在擁有 348 股該健康服務提供商的股票，價值 32,000 美元，此前在上一季度增持了 141 股。Caitong International Asset Management Co. Ltd 在第二季度購買了 Amedisys 的新頭寸，價值約 32,000 美元。最後，UMB Bank n.a.在第一季度將其在 Amedisys 的持股增加了 100.0%。UMB Bank n.a.現在擁有 386 股該健康服務提供商的股票，價值 36,000 美元，此前在上一季度增持了 193 股。對沖基金和其他機構投資者持有該公司 94.36% 的股份。</p>
<h2>Amedisys 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Amedisys, Inc.及其子公司在美國提供醫療服務。它通過三個部門運營：家庭健康、臨終關懷和高強度護理。家庭健康部門為患者從手術、慢性殘疾或絕症的恢復提供一系列服務，並通過其專業護士預防可避免的住院再入；護理服務、專注於物理、語言和職業治療的康復治療師；以及社工和助理來協助患者。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Amedisys 更好</li>
<li>國會股票交易跟蹤</li>
<li>微軟股票上漲，分析師提高目標價</li>
<li>什麼是股息冠軍？如何投資於冠軍</li>
<li>宇宙能源的盈利超出預期，標誌着一個新時代</li>
<li>如何在 5 個簡單步驟中做空股票</li>
<li>4 只半導體股票獲得華爾街的新評級</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Amedisys 嗎？</h2>
<p>在你考慮 Amedisys 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Amedisys 並不在名單上。</p>
<p>雖然 Amedisys 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

阿米斯醫療

<p>Amedisys（納斯達克代碼：AMED）交易量顯著增加，成交量達到 1,188,750 股，比前一交易日上漲 215%。股價從 99.29 美元上漲至 100.88 美元。分析師們的看法不一，加拿大皇家銀行維持 “跑贏大盤” 評級，目標價為 100 美元，而華爾街 Zen 則將其評級下調至 “買入”。Amedisys 報告每股收益為 1.54 美元，超出預期，收入為 6.2186 億美元，同比增長 5.2%。對沖基金持有該股票的 94.36%，顯示出強烈的機構興趣</p>

<p>Amedisys, Inc. (NASDAQ:AMED - Get Free Report) saw an uptick in trading volume on Thursday . 1,188,750 shares were traded during mid-day trading, an increase of 215% from the previous session's volume of 377,256 shares.The stock last traded at $100.88 and had previously closed at $99.29.</p>
<div class="lb-trans"><p>Amedisys, Inc.（納斯達克代碼：AMED - 獲取免費報告）在週四的交易量有所上升。中午交易時段交易了 1,188,750 股，較前一交易日的 377,256 股增加了 215%。該股票最後交易價格為 100.88 美元，之前收盤價為 99.29 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of equities analysts have recently issued reports on AMED shares. Royal Bank Of Canada reissued an &#34;outperform&#34; rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Wall Street Zen downgraded shares of Amedisys from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, May 24th.</p>
<div class="lb-trans"><p>一些股票分析師最近對 AMED 股票發佈了報告。加拿大皇家銀行在 4 月 16 日的研究報告中重申了對 Amedisys 的 “跑贏大盤” 評級，並設定了 100.00 美元的目標價。Wall Street Zen 在 5 月 24 日的研究報告中將 Amedisys 的評級從 “強力買入” 下調至 “買入”。</p>
</div><p><strong>Check Out Our Latest Stock Report on Amedisys</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Amedisys 股票報告</strong></p>
</div><h2>Amedisys Stock Up 1.6%</h2>
<div class="lb-trans"><h2>Amedisys 股票上漲 1.6%</h2>
</div><p>The company has a current ratio of 1.36, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The business's 50-day simple moving average is $97.08 and its 200-day simple moving average is $94.31. The company has a market capitalization of $3.32 billion, a PE ratio of 39.25, a price-to-earnings-growth ratio of 1.34 and a beta of 0.89.</p>
<div class="lb-trans"><p>該公司的流動比率為 1.36，速動比率為 1.36，債務與股本比率為 0.26。該公司的 50 日簡單移動平均線為 97.08 美元，200 日簡單移動平均線為 94.31 美元。公司的市值為 33.2 億美元，市盈率為 39.25，市盈增長比率為 1.34，貝塔值為 0.89。</p>
</div><p>Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The business had revenue of $621.86 million for the quarter, compared to analyst estimates of $614.61 million. During the same quarter last year, the business earned $0.98 earnings per share. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Amedisys（納斯達克代碼：AMED - 獲取免費報告）最後一次公佈財報是在 7 月 29 日，健康服務提供商報告每股收益（EPS）為 1.54 美元，超出市場普遍預期的 1.39 美元，超出 0.15 美元。Amedisys 的淨利潤率為 3.56%，股本回報率為 12.91%。該公司本季度的收入為 6.2186 億美元，而分析師預期為 6.1461 億美元。去年同期，該公司的每股收益為 0.98 美元。本季度的收入較去年同期增長了 5.2%。整體來看，股票研究分析師預計 Amedisys, Inc.在本財年的每股收益將達到 4.4 美元。</p>
</div><h2>Hedge Funds Weigh In On Amedisys</h2>
<div class="lb-trans"><h2>對 Amedisys 的對沖基金觀點</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hexagon Capital Partners LLC lifted its stake in Amedisys by 108.1% in the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock worth $29,000 after acquiring an additional 161 shares during the last quarter. MassMutual Private Wealth &amp; Trust FSB boosted its holdings in Amedisys by 56.1% in the first quarter. MassMutual Private Wealth &amp; Trust FSB now owns 334 shares of the health services provider's stock valued at $31,000 after purchasing an additional 120 shares in the last quarter. Fifth Third Bancorp increased its stake in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after purchasing an additional 141 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Amedisys in the second quarter valued at approximately $32,000. Finally, UMB Bank n.a. raised its holdings in Amedisys by 100.0% during the first quarter. UMB Bank n.a. now owns 386 shares of the health services provider's stock worth $36,000 after purchasing an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Hexagon Capital Partners LLC 在第一季度將其在 Amedisys 的持股增加了 108.1%。Hexagon Capital Partners LLC 現在擁有 310 股該健康服務提供商的股票，價值 29,000 美元，此前在上一季度增持了 161 股。MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在 Amedisys 的持股增加了 56.1%。MassMutual Private Wealth &amp; Trust FSB 現在擁有 334 股該健康服務提供商的股票，價值 31,000 美元，此前在上一季度增持了 120 股。Fifth Third Bancorp 在第一季度將其在 Amedisys 的持股增加了 68.1%。Fifth Third Bancorp 現在擁有 348 股該健康服務提供商的股票，價值 32,000 美元，此前在上一季度增持了 141 股。Caitong International Asset Management Co. Ltd 在第二季度購買了 Amedisys 的新頭寸，價值約 32,000 美元。最後，UMB Bank n.a.在第一季度將其在 Amedisys 的持股增加了 100.0%。UMB Bank n.a.現在擁有 386 股該健康服務提供商的股票，價值 36,000 美元，此前在上一季度增持了 193 股。對沖基金和其他機構投資者持有該公司 94.36% 的股份。</p>
</div><h2>Amedisys Company Profile</h2>
<div class="lb-trans"><h2>Amedisys 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.</p>
<div class="lb-trans"><p>Amedisys, Inc.及其子公司在美國提供醫療服務。它通過三個部門運營：家庭健康、臨終關懷和高強度護理。家庭健康部門為患者從手術、慢性殘疾或絕症的恢復提供一系列服務，並通過其專業護士預防可避免的住院再入；護理服務、專注於物理、語言和職業治療的康復治療師；以及社工和助理來協助患者。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Amedisys</li>
<li>Following Congress Stock Trades</li>
<li>Microsoft Stock Gains as Analysts Boost Price Targets</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Constellation Energy’s Earnings Beat Signals a New Era</li>
<li>How to Short a Stock in 5 Easy Steps</li>
<li>4 Semiconductor Stocks Earning Fresh Wall Street Upgrades</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Amedisys 更好</li>
<li>國會股票交易跟蹤</li>
<li>微軟股票上漲，分析師提高目標價</li>
<li>什麼是股息冠軍？如何投資於冠軍</li>
<li>宇宙能源的盈利超出預期，標誌着一個新時代</li>
<li>如何在 5 個簡單步驟中做空股票</li>
<li>4 只半導體股票獲得華爾街的新評級</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amedisys Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Amedisys 嗎？</h2>
</div><p>Before you consider Amedisys, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Amedisys 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Amedisys 並不在名單上。</p>
</div><p>While Amedisys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amedisys 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

阿米斯醫療（NASDAQ:AMED）出現異常高的交易量 - 原因如下